Articles published by Seagen Inc.

Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023

January 19, 2023

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen to Present at the J.P. Morgan Healthcare Conference

December 20, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

December 20, 2022

From Seagen Inc.

Via Business Wire

Tickers MRK SGEN

Seagen Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

December 12, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen to Highlight ADCETRIS® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting

December 01, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting

November 10, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen Announces U.S. FDA Approval of New Indication for ADCETRIS® (brentuximab vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

November 10, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen Appoints Sandra M. Swain, M.D., to Board of Directors

November 10, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen Names David R. Epstein as Chief Executive Officer and Director

November 10, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen Reports Third Quarter 2022 Financial Results

October 27, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022

October 06, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

September 27, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN ZLAB

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

September 26, 2022

From Seagen Inc.

Via Business Wire

Tickers LVTX SGEN

Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

September 19, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

September 12, 2022

From Seagen Inc.

Via Business Wire

Tickers MRK SGEN

Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress

September 07, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

September 07, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen Statement on Outcome of Daiichi Sankyo Arbitration

August 12, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen Reports Second Quarter 2022 Financial Results

July 28, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

July 26, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022

July 08, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer

July 02, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

June 06, 2022

From Seagen Inc.

Via Business Wire

Tickers GMAB SGEN

ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma

June 03, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer

May 23, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen Announces Resignation of President, Chairman & CEO Clay Siegall

May 16, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence

May 09, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen Reports First Quarter 2022 Financial Results

April 28, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

April 28, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines

April 20, 2022

From Seagen Inc.

Via Business Wire

Tickers SGEN

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.